Regeringen vill ge pengar till läkemedelsbolag för att skynda på utvecklingen av antibiotika som står emot motståndskraftiga bakterier köpa inderal receptfritt Svenska materialet kan bli alternativ till antibiotika.

Microsoft word - grantsdec06.doc

GRANTS: DECEMBER 2006
UNWILLING TO PRESCRIBE NEEDED MEDICATION? EMERGENCY DEPT BY CHRONIC PAIN PATIENTS TO BARRIERS TO TREATMENT, ABUSIVE BEHAVIORS AND PSYCHOLOGICAL FACTORS VOLATILE ANESTHETIC ACTION IN VERTEBRATE LOCOMOTOR SYSTEMS POTASSIUM CHANNELS BY NITRIC OXIDE AND NEUROPROTECTION DYNAMIC ANALYSES OF LEARNING IN BEHAVIORAL EXPERIMENTS A COMPARISON OF THE ADDICTION LIABILITY OF HYDROCODONE AND DEMOGRAPHIC, SOCIOECONOMIC AND GENETIC FACTORS IN SLE STEM CELLS AS MEANS FOR DECREASING BREAST MOLECULAR ANALYSIS OF OCULAR LENS BEADED DEVELOPMENT OF THE OLFACTORY CONNECTIONS ANALYZING MYC FUNCTION IN NEURAL DEVELOPMENT AND CANCERS SPERM GLYCINE RECEPTORS AND ZONA-INITIATED EXOCYTOSIS CTR FOR DEVELOPMENT OF ANTISPERM CONTRACEPTIVES THE FUNCTIONS OF TENEURINS IN THE DEVELOPING VISUAL UC DAVIS CLINICAL AND TRANSLATIONAL SCIENCE INTEGRATING MEDICINE INTO BASIC SCIENCE AT UC RESEARCH FACILITIES IMPROVEMENT PROJECT FOR STATEWIDE INITIATIVE TO DISSEMINATE END OF LIFE IMPROVE SHARED DECISION MAKING: PROSTATE NICOTINIC RECEPTORS ALTER GENE EXPRESSION TOBACCO SMOKE INDUCED LUNG TUMORS IN A/J MICE? keratinocyte galvanotaxis and wound healing AN OPEN LABEL STUDY TO EVALUATE WHETHER A PATIENTS TREATED WITH EFALIZUMAB IS SAFE AND INTEGRINS AND PRO-INFLAMMATORY SECRETORY INTEGRINS AND PRO-INFLAMMATORY SECRETORY AUDICOR TECHNOLOGY FOR RAPID DIAGNOSIS AND INITIAL TREATMENT OR TESTING AND INITIAL STRATEGY FOR TREATMENT PREDICTING CERVICAL SPINE INJURY IN CHILDREN gun watch: reducing gun violence through evidence AMERICAN CANCER SOCIETY MENTORED RES SCHOLAR SONG BROWN PRIMARY CARE PHYSICAN ASSISTANT AND FAMILY NURSE PRACTITIONER TRAINING PROG PHYSICIAN ASSISTANT TRAINING IN PRIMARY CARE EL CAMINO A LA SALUD: CANCER PRIORITIES IN THE CANCER PRIORITIES IN THE LATINO POPULATION surveillance strategies following treatment for following treatment for cervical INTRAEPITHELIAL LUNAR: A 12 WEEK, RANDOMIZED, OPEN LABEL, 3 ARM, PARALLEL GROUP, MULTICENTER, PHASE IIIB STUDY COMPARING THE EFFICACY AND SAFETY OF ATORVASTATIN 80MG IN SUBJECTS WITH ACUTE CORONARY SYNDROMES TELMISARTAN ALONE AND IN COMBINATION WITH promote reverse electrical remodeling of the atria? (01- ASSESSMENT OF CHEST PAIN IN THE EMERGENCY CLIRPATH EXCIMER LASER SYSTEM TO ENLARGE TAXUS IV-SR: TREATMENT OF DE NOVO CORONARY DISEASE USING A SINGLE PACLITAXEL-ELUTING STENT PERCUTANEOUS CORONARY INTERVENTION (ICE-IT) DOUBLE BLIND TRIAL TO ASSESS TAXUS PACLITAXEL- ELUTING CORONARY STENTS, SLOW-RELEASE FORMULATION A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AD5FGF-4 IN PATIENTS WITH STABLE FACTOR: FLOWCARDIA’S APPROACH TO CHRONIC TOTAL OCCLUSION RECANALIZATION: CLINICAL INVESTIGATIONAL WATCHMAN LEFT ATRIAL APPENDAGE FILTER SYSTEM US IDE PILOT CLINICAL STUDY INVESTIGATIONAL APPENDAGE SYSTEM FOR EMBOLIC PROTECTION IN PATIENTS WITH ATRIAL FIBRILLATION: US IDE PIVOTAL CLINICAL STUDY INVESTIGATIONAL PLAN STUDY OF THE EVALVE CARDIOVASCULAR VALVE REPAIR SYSTEM (CVRS) TRIAL OF THE MEDTRONIC ENDEAVOR DRUG (ABT-578) ELUTING CORONARY STENT SYSTEM VERSUS THE TAXUS PACLITAXEL ELUTING CORONARY STENT SYSTEM IN DE NOVO NATIVE CORONARY ARTERY LESIONS A PHASE I-II, MULTICENTER, RANDOMIZED, DOUBLE STUDY TO EVALUATE THE SAFETY AND POTENTIAL EFFICACY OF SINGLE, INCREASING DOSES OF TG100-115 IN SUBJECTS INTERVENTION FOR ACUTE ST ELEVATION MYOCARDIAL MITOCHONDRIAL CALCIUM ENTRY THROUGH VDAC THERAPY OPTIMIZATION WITH V-V TIMING IN HEART FAILURE PATIENTS H7T-MC-TAAL: A COMPARISON OF CS-747 AND CLOPIDOGREL IN AND NATIONAL COMMUNITY CARDIOVASCULAR DISEASE FOR IMPLANTABLE CARDiOVERTER DEFIBRILLATOR THERAPY WIRELESS, AUTOMATIC, MOBILE MONITORING FOR RISK REDUCTION EVAL WITH ICD IMPLANTATIONS THE APPROACH STUDY: A PHASE III, MULTICENTER, ROSIGLITAZONE VERSUS GLIPIZIDE ON THE PROGRESSION OF DIABETES MELLITUS AND CARDIOVASCULAR DISEASE EFFECTS OF SAM IN PATIENTS WITH ALCOHOLIC SAME AND FOLATE DEFICIENCY IN ALCOHOLIC MICROPIGS MRI DEVELOPMENT OF OMX: A STRUCTURED ILLUMINATION MICROSCOPE SYSTEM WITH SUB-100 NM SPATIAL RESOLUTION FOR LUTEINIZING HORMONE SECRETION MECHANISMS peptide surface modification to prevent stent blockage ADVANCED ERCP TECHNIQUES: A PILOT STUDY FROM A UNIVERSITY PLUS REBETOL VS. PEG-INTRON 1UG/KG/WK PLUS REBETOL VS. PEGASYS 180 UG/KG/WK PLUS COPEGUS IN PREVIOUSLY UNTREATED ADULT SUBJECTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE 1 A PROSPECTIVE MULTICENTER, OPEN LABEL, COMPARATIVE EFFICACY STUDY OF PEGASYS PLUS COPEGUS IN TREATMENT OF NAIVE LATINO PATIENTS WITH CHRONIC HEPATITIS C - GENETYPE 1, AS COMPARED TO TREATMENT NAIVE NON LATINO CAUCASIAN PATIENTS WITH CHRONIC HEPATITIS C A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF RIFAXIMIN 550 MG BID PHASE II, RANDOMIZED, MULTICENTER, DOUBLE INHIBITOR PRODRUG (RO4588161) WHEN GIVEN IN COMBINATION WITH PEGASYS WITH OR WITHOUT COPEGUS VERSUS THE CURRENTLY APPROVED COMBINATION OF PEGASYS PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 BLIND, STUDY EVALUATING THE EFFICACY (AS MEASURED BY SUSTAINED VIROLOGICAL RESPONSE) AND SAFETY OF 360 UG INDUCTION DOSING OF PEGASYS IN COMBINATION WITH HIGH COPEGUS DOSES IN TREATMENT OF GENOTYPE 1 VIRUS INFECTION OF HIGH VIRAL TITER AND BASELINE BODY WEIGHT GREATER THAN OR OXIDATIVE INJURY IN LIVER CARCINOGENESIS ASSESSING PREVENTION AND EARLY INTERVENTION NEEDS THROUGH A CULTURALLY TARGETED APPROACH TO MEDICATION ELDERLY PATIENTS WITH IDIOPATHIC ANEMIA OF CONTROLLED STUDY TO ASSESS CHANGES IN PHYSICAL FUNCTION IN ELDERLY PATIENTS WITH ANEMIA OF A CHRONIC HETEROGENEITY OF TREATMENT EFFECTS IN THE improving care for comorbid physical and mental illnesses PARATHYROID HORMONE 1-34 (HPTH 1-34) REVERSE GLUCOCORTICOID INDUCED GLUCOCORTICOIDS AND RISEDRONATE AFTER BONE STRENGTH BY REGULATING EXPRESSION OF GENES pArallel arm, placebo controlled, double blind multiple dose study to investigate the safety and efficacy of rn624 in patients SAFETY AND TOLERABILITY OF AMG 162 IN THE the breast cancer experience of slavic women FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 COMPARED TO PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POST A PHASE III RANDOMIZED STUDY OF EXEMESTANE POSTMENOPAUSAL WOMEN AT INCREASED RISK OF DEVELOPING BREAST CARDIOVASCULAR HEALTH STUDY - TRANSITION PHASE CONTROLLED TRIAL TO IMPROVING PALLIATIVE CARE THROUGH LONGITUDINAL WEB-BASED ACTIVATION OF RESIDENTS CENTER STUDY OF THE EFFICACY AND SAFETY OF NATEGLINIDE AND VALSARTAN IN THE PREVENTION OF DIABETES CONTROLLED EVALUATION OF CLOPIDOGREL PLUS IRBESARTAN, FOR THE PREVENTION OF VASCULAR EVENTS, IN PATIENTS WITH evaluate the accuracy of anti-fibrin humanized monoclonal antibody (di-dd3b6/22-80b3) fab protein fragment conjugated with technetium in the detection INVOLVING PATIENTS WITH IDIOPATHIC VENOUS A PHASE II, MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE B ANTIBODY (MONOCLONAL ANTI-BLYS ANTIBODY) IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (LBSL02) AND A MULTICENTER, OPEN LABEL, CONTINUATION TRIAL OF FOR THE EVALUATION OF THE SAFETY, TOLERABILITY AND EFFICACY OF MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY PROFESSIONAL USE AT THE POINT OF CARE CLINICAL ANTICOAGULANT THERAPY (RE-LY) COMPARING THE EFFICACY AND SAFETY OF TWO BLINDED DOSES WARFARIN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLIC EVENTS IN PATIENTS WITH NON VALVULAR ATRIAL THE ONCOTYPE DX ASSAY FOR ESTROGEN RECEPTOR POSITIVE, NODE NEGATIVE BREAST CARCINOMA: DOES IT IMPACT ON PHYSICIAN ADJUVANT TREATMENT BLIND, STRATIFIED, PLACEBO CONTROLLED, MULTICENTER, 3-ARM TRIAL A PHASE I/II STUDY OF TWO DIFFERENT SCHEDULES OF BORTEZOMIB (PS-341) AND PEMETREXED IN ADVANCED SOLID TUMORS, WITH EMPHASIS ON NON-SMALL RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PEMETREXEL) ALONE FOR TREATMENT OF RECURRENT OR REFRACTORY NON-SMALL CELL LUNG CANCER CISPLATIN VERSUS GEMZAR (GEMCITABINE) AND CISPLATIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL phase i/ii study of erlotinib (tarceva) and cetuximab (erbitux) in advanced solid tumors, with emphasis on PHASE II OPEN LABEL, MULTICENTER CLINICAL STUDY OF THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF SNS- 595 IN PATIENTS WITH ADVANCED SMALL CELL AND DNA REPAIR GENES TO ENHANCE RADIATION 43-9006 IN PATIENTS WITH PLATINUM-TREATED 572016 IN LOCALLY ADVANCED OR METASTATIC REAGENTS AND ASSAYS FOR STRUCTURE BASED PATHOGEN DETECTION THERAPEUTIC TARGETING AGENTS FOR OVARIAN A PHASE III RANDOMIZED STUDY OF BAY 43-9006 IN NATIONAL, DOUBLE BLIND, RANDOMIZED PHASE III PLACEBO PLUS PREDNISONE IN PATIENTS WITH HORMONE REFRACTORY BONE TURNOVER IN METASTATIC PROSTATE CANCER DECISION MAKING, PATIENT CAREGIVER DISTRESS AND CULTURALLY APPROPRIATE CARE IN CANCER PATIENT POPULATION CORRELATIVE STUDIES FOR CLINICAL PROTOCOL P7097: A PHASE II STUDY OF AZD 2171 IN PATIENTS WITH RECURRENT SMALL CELL CORRELATIVE STUDIES FOR CLINICAL PROTOCOL P7077: A RANDOMIZED PHASE II TRIAL OF SEQUENTIAL VERSUS CONCURRENT DOCETAXEL AND PS-341 IN PREVIOUSLY TREATED NON SMALL CELL LUNG CANCER HYPOXIA INDUCED PROTEINS AS LUNG CANCER BIOMARKERS A RANDOMIZED, TWO WAY BLINDED CROSSOVER DESIGN STUDY TO WITH A FULL LENGTH RECOMBINANT FACTOR VIII PREPARATION FOLLOWED BY AN OPEN LABEL TRIAL OF THE SAFETY AND EFFICACY blinded crossover study to determine the pharmacokinetics and safety of a single intravenous infusion of bay 79-4980 recombinant factor viii formulated with sucrose reconstituted with 9% pegylated liposome diluent (bay 79-4979) in previously treated patients with severe a randomized two way blinded crossover study to determine the pharmacokinetics and safety of a single intravenous infusion of bay 79-4980 recombinant factor viii formulated with sucrose reconstituted with 9% pegylated liposome diluent (bay 79-4979) in previously treated patients with severe hemophIlia a PREVENTING BLEEDING DISORDER COMPLICATIONS A MULTICENTER, SINGLE ARM, OPEN LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE AGENT RELAPSED OR REFRACTORY AGGRESSIVE NON HODGKIN LYMPHOMA DOXIL-MMY-3001: A RANDOMIZED CONTROLLED STUDY OF DOXIL/CAELYX AND VELCADE OR VELCADE MONOTHERAPY FOR THE A PHASE III, MULTICENTER, 52-WEEK, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE CLINICAL EFFICACY AND HYDROXYUREA THERAPY IN PATIENTS WITH SICKLE CELL DISEASE WHO HAVE HAD TWO ACUTE SICKLE RELATED PAINFUL CRISES CELL CTR CLINICAL TRIALS CONSORTIUM (CSCC CTC) IMMUNOGENICITY OF THE MERCK TRIVALENT ADENOVIRUS SEROTYPE 5 HIV-1 GAG/POL/NEF VACCINE IN A PRIME BOOST IMMUNOGENICITY OF A 3-DOSE REGIMEN OF THE MRKAD5 HIV-1 TRIGENE AND THE MRKAD6 HIV-1 TRIGENE VACCINES ALONE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF HUMAN IMMUNDEFICIENCY VIRUS TYPE 1 GAG DNA BUFFERED SALINE OR WITH ALUMINUM PHOSPHATE, FOLLOWED BY AD5 HIV-1, IMMUNOGENICITY OF HUMAN IMMUNODEFICIENCY VIRUS TYPE I (HIV-1) GAG DNA FORMULATED WITH ADENOVIRUS SEROTYPE 5 HIV-1 VACCINE (AD5 HIV-1 GAG) IN A PRIME/BOOST MULTICENTER, DOUBLE BLINDED, PHASE IV STUDY COMPARING THE SAFETY AND EFFICACY OF PEGASYS 180 UG PLUS COPEGUS 1000 (75< KG) OR 1200 MG (>75 KG) TO THE CURRENTLY APPROVED COMBINATION OF PEGASYS 180 UG PLUS COPEGUS 800 MG IN INTERFERON-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 VIRUS INFECTION CO-INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS STAPHYLOCOCCUS AUREUS (MRSA) INFECTION AMONG MINORITY AIDS INITIATIVE, STREET OUTREACH DIRECTLY OBSERVED PREVENTION INTERVENTION STRATEGIES WITH HIV INFECTED PERSONS AS SEEN IN FOUR DIFFERENT (TELBIVUDINE) VERSUS LAMIVUDINE IN ADULTS WITH COMPENSATED CHRONIC HEPATITIS B: NV- A PILOT I/II RANDOMIZED PLACEBO CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFICACY OF ANTIBODY TITERS IN PATIENTS WITH OR AT HIGH RISK FOR PROGRESSION TO WEST NILE VIRUS ENCEPHALITIS OF MYELITIS SAFETY AND EFFICACY OF SEROSTIM (MAMMALIAN CELL DERIVED RECOMBINANT HUMAN GROWTH HORMONE, R- HGH) IN THE TREATMENT AND MAINTENANCE OF A PHASE I, MULTICENTER, RANDOMIZED, DOUBLE BLIND, ADJUVANT CONTROLLED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF AN HIV CTL MULTI-EPITOPE AND GM-CSF GIVEN TO HIV-1 POSITIVE ADULTS CALIFORNIA RES CTR FOR THE BIOLOGY OF HIV IN CLINICAL AND LABORATORY PROTOCOL FOR THE STUDY OF GUAVA TECHNOLOGY EASY CD4 INSTRUMENT SYSTEM AND GUAVA EASY AN OPEN LABEL TRIAL WITH TMC125 IN HIV-1 INFECTED SUBJECTS, WHO WERE RANDOMIZED TO A TMC125 TMC125 TRIAL AND WERE TREATED FOR AT LEAST 48 AN OPEN LABEL TRIAL OF TELBIVUDINE (LDT) IN ADULTS WITH CHRONIC HEPATITIS B PREVIOUSLY ELVUCITABINE VERSUS LAMIVUDINE ADMINISTERED ONCE DAILY BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY AND ANTIRETROVIRAL ACTIVITY OF MK-0518 VERSUS EFAVIRENZ IN TREATMENT NAIVE HIV INFECTED PATIENTS, EACH IN COMBINATION WITH CYSTEINE SULFENIC ACIDS: IMPLICATIONS FOR THE EFFECT OF ETANERCEPT IN SUPPRESSION OF THE LOW MOLECULAR WEIGHT UREMIC TOXINS PRODUCED BY INFLAMMATORY OXIDATIVE PATHWAYS: THE EFFECTS OF USING INTRAVENOUS INJECTIONS OF RO0503821 IN PATIENTS WITH CHRONIC KIDNEY DISEASE WHO ARE ON DIALYSIS THE EFFECT OF ETANERCEPT TNFR:FC IN SUPPRESSION OF THE SYSTEM INFLAMMATORY RESPONSE IN HEMODIALYSIS PATIENTS ATHEROSCLEROSIS AND INFLAMMATION IN DIALYSIS CLINICAL RES NETWORK FOR THE TREATMENT OF ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME A LONG TERM STUDY OF AMBRISENTAN IN PULMONARY ARTERIAL HYPERTENSION SUBJECTS HAVING COMPLETED AMB- HEMODYNAMIC EFFECTS OF UT-15C SR IN SUBJECTS VISION C200-006: A RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF INHALED ILOPROST IN PATIENTS WITH PULMONARY hemodynamics in patients with pulmonary arterial hypertension associated with EFFICACY AND SAFETY OF ORAL UT-15C SUSTAINED RELEASE TABLETS IN SUBJECTS WITH PULMONARY ARTERIAL GENETICS IN SUBJECTS WITH PULMONARY ARTERIAL PROTOCOL TDE-PH-302: A 12 WEEK, INTERNATIONAL, MULITCENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED COMPARISON OF THE EFFICACY AND SAFETY OF ORAL UT-15C SUSTAINED RELEASE TABLETS IN TDE-PH-304: AN OPEN LABEL EXTENSION TRIAL OF UT-15C IN PATIENTS WITH PULMONARY ARTERIAL placebo controlled, phase iii study of the efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE III, THREE ARM STUDY OF THE SAFETY AND EFFICACY OF RANDOMIZED, DOUBLE BLIND STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE EXHALE DRUG ELUTING GENOMIC RESPONSES OF THE LUNGS TO TOBACCO PROTECTIVE ROLE FOR NITRIC OXIDE IN AIRWAY ATTENUATION OF MUCOUS CELL METAPLASIA BY RAD A RANDOMIZED, OPEN LABEL, MULTICENTER PHASE 3 TRIAL TO ASSESS THE SAFETY OF TOBRAMYCIN HOMEOSTASIS PLAY A ROLE IN ENDOTHELIN MEDIATED ENDOTHELIAL TRAINING IN COMPARATIVE LUNG BIOLOGY AND IL-17 MEDIATED MUC GENE EXPRESSION IN AIRWAY MURINE MODEL OF PRIMARY BILIARY CIRRHOSIS PATHOGENESIS OF PRIMARY BILIARY CIRRHOSIS B CELL AND AMA RESPONSE IN PATIENTS WITH PRIMARY XENOBIOTICS of PRIMARY BILIARY CIRRHOSIS EPIGENETICS OF X-LINKED GENES IN PBC: DOES X JUICE CONSTITUENTS ON THE ANTIBODY RESPONSE PRENATAL AND NEONATAL BIOLOGICAL MARKERS FOR A SCREEN FOR POTENTIAL EARLY BIOMARKERS OF NOVEL MEMBRANE PROTEINS IN SYNAPSE FORMATION transmembrane proTeins that regulate synaptic BLOCKERS AS NEW THERAPEUTICS FOR MULTIPLE SCLEROSIS DRUG FOR RESTENOSIS, TRANSPLANT REJECTION A MULTICENTER STUDY TO EVALUATE THE EFFECT OF PARASPINAL MUSCULATURE USING HIGH RESOLUTION LUMBAR DEGENERATIVE DISC DISEASE TREATED WITH ANTERIOR TENSION BAND SYSTEM (ATB) WITH SEALANT SYSTEM AS AN ADJUNCT TO SUTURED DURAL REPAIR WITH RANDOMIZED, CONTROLLED CLINICAL TRIAL COMPARING MOBI-C PROSTHESIS TO CONVENTIONAL ANTERIOR CERVICAL DISCECTOMY AND DEGENERATIVE DISC DISEASE IN THE CERVICAL INFIX INTERBODY FUSION STUDY - CHART AUDIT POSTOPERATIVE EPIDURAL FIBROSIS AND RELATED A RANDOMIZED, RATER-BLINDED, MULTICENTER, PARALLEL GROP STUDY COMPARING THE EFFICACY AND SAFETY OF BETASERON 250MG SUBCUTANEOUSLY EVERY OTHER DAY WITH PER WEEK IN RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS PREVIOUSLY TREATED WITH MULTICENTER, PHASE III STUDY IN PATIENTS WITH RELAPSING-REMITTING multicenter, randomized, double-blind, placebo controlled, parallel group study to evaluate the effect of early glatiramer acetate treatment in delaying the conversion to clinically definite multiple sclerosis of subjects presenting with a A 24-WK, RANDOMIZED, DOUBLE BLIND, PARALLEL ANTIBODY ABT-874 IN SUBJECTS WITH MULTIPLE SCLEROSIS WITH A 24-WK BLIND, PARALLEL GROUP STUDY TO COMPARE THE EFFICACY, TOLERABILITY AND SAFETY OF COPAXONE TO THAT OF HIGH DOSE INTERFERON IN THE TREATMENT OF RELAPSING OPEN LABEL, RANDOMIZED, STUDY OF REBIF 44MCG SUBCUTANEOUS INJECTION COMPARED WITH COPAXONE 20MG ADMINISTERED DAILY BY SUBCUTANEOUS INJECTION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF NATAZILUMAB IN SUBJECTS WITH MULTIPLE SCLEROSIS WHO HAVE COMPLETED STUDIES C-1801, C-1802 OR C-1803 BLIND, RANDOMIZED STUDY COMPARING THE COMBINED USE OF INTERFERON BETA-1A AND GLATIRAMER ACETATE TO EITHER AGENT ALONE IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS (COMBIRX-PHASE III) CANNABIS FOR SPASTICITY IN MULTIPLE SCLEROSIS: OPEN LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND ACTIVITY OF ORAL FAMPRIDINE-SR IN SUBJECTS WITH MULTIPLE SCLEROSIS WHO MULTICENTER, EXTENSION STUDY TO EVALUATE THE FOLLOWING RE-INITIATION OF DOSING IN MULTIPLE SCLEROSIS SUBJETS WHO HAVE COMPLETED STUDY C-1801, C-1802 OR C-1803 MULTICENTER, PLACEBO CONTROLLED, PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF 0.5 MG AND 1.25 MG FINGOLIMOD (FTY720) ADMINISTERED ORALLY ONCE DAILY VERSUS PLACEBO IN PATIENTS WITH GROUP, DOUBLE BLIND STUDY TO COMPARE THE EFFICACY, TOLERABILITY AND SAFETY OF GLATIRAMER ACETATE INJECTION 40 MG/ML TO THAT OF GLATIRAMER TRAINING IN CLINICAL TRIALS: ESSENTIAL FOR A CAREER IN MULTIPLE CALIFORNIA NON-AD DIAGNOSTIC RELIABILITY STUDY CL-758007, A PHASE III STUDY OF THE EFFICACY AND SAFETY OF ALZHEMED IN PATIENTS WITH MILD TO CONTROLLED, MULTIPLE ASCENDING DOSE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMOCODYNAMIC AND IMMUNOGENICITY TRIAL OF AAB-001 IN PATIENTS WITH STROKE INCIDENCE AND RISK FACTORS IN A TRI- HETEROGENEITY OF MILD COGNITIVE IMPAIRMENT FUNCTIONAL EFFECTS OF CONGENITAL MYASTHENIA PREDICTION OF EVERYDAY FUNCTION DEMENTIA OLIGODENDROGLIAL DEATH BY THE BC1 FAMILY USE OF ALLELE-SPECIFIC SMALL INTERFERING RNAS FOR TREATMENT OF SLOW CHANNEL CONGENITAL MORPHOLOGIC CHANGES INDUCED BY SOMAN AT THE HUMAN NEUROMUSCULAR CELLULAR MECHANISMS OF MENTAL RETARDATION REGULATION OF NMDAR TRAFFICING AND FUNCTION PROTEINS IN EARLY STAGES OF NEURAL DEVELOPMENT: POSSIBLE IMPLICATIONS AGING BRAIN: VASCULAR, ISCHEMIA AND BEHAVIOR - PATIENTS WITH FAMILIAL TOURETTE’S SYNDROME PLACEBO CONTROLLED STUDY OF AGGRENOX VS. CLOPIDOGREL AND A MULTICENTER, DOUBLE BLIND, PARALLEL GROUP, (MIRAXION) IN PATIENTS WITH MILD TO MODERATE IS GLUTATHIONE OR ANOTHER SULFHYDRYL-REDUCING AGENT THE TRIGGER OF AUTOIMMUNE MYASTHENIA GRAVIS? CLINICAL ACTIVITY AND SAFETY OF TWO DOSE LEVELS OF SUBCUTANEOUS A6 IN PATIENTS WITH ASYMPTOMATIC CA125 PRIMARY PERITONEAL CARCINOMA AFTER FIRST CALIFORNIA EXPANDED AFP SCREENING PROGRAM MID-LIFE AGING AND URINARY INCONTINENCE IN a multicenter, randomized, open label study to compare subconjunctival injections of 100ug cat-152 human anti- tgfB2 monoclonal antibody with an intraoperative sponge application of 5-fluorouracil following first FOCUSED DELIVERY OF LASER ENERGY TO THE EYE USING ADAPTIVE OPTICS AGE RELATED EPIGENETIC GENE SILENCING IN THE RPE STUDY OF THE STENT TRABECULAR BYPASS MICRO STENT IN POSTERIOR JUXTASCLERAL ADMINISTRATIONS OF ANECORTAVE ACETATE FOR DEPOT SUSPENSION (15MG OR 30MG) VERSUS SHAM STUDY "A" OR STUDY "B") AT RISK FOR DEVELOPING SIGHT-THREATENING CHOROIDAL NEOVASCULARIZATION (CNV) DUE TO EXUDATIVE AGE-RELATED MACULAR a six month, phase III multicenter, masked randomized, sham-controlled trial (with six month open label extensioin) to assess the safety and efficacy of 700 mg and 350 mg dexamethasone posterior segment drug delivery system in the treatment of patients with macular edema following central retinal vein occlusion of branch-vein STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RANIBIZUMAB IN SUBJECTS WITH SUBFOVEAL SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE A PHASE IIIB, SINGLE MASKED, MULTICENTER, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF RANIBIZUMAB IN NAIVE AND PREVIOUSLY TREATED LOWERING AGENTS REDUCE APOPTOSIS AND TISSUE SPECIFIC CHOLESTEROL DEPOSITS INDUCED IN MICE FED FOR PATIENTS COMPLETING STUDY B7A-MC-MBCM MULTICENTER, MASKED, RANDOMIZED SHAM-CONTROLLED TRIAL TO DELIVERY SYSTEM (DEX PS DDS) APPLICATOR SYSTEM IN THE TREATMENT OF PATIENTS WITH DIABETIC CORNEAL METALLOPROTEINASE MATRIX INTERACTIONS THE EFFECTS OF EMBRYONIC STEM CELLS ON A MURINE MODEL OF A RANDOMIZED, DOUBLE MASKED, PARALLEL GROUP, THE SAFETY AND EFFICACY OF ASI-001A 0.5 UG/DAY AND ASI-001A 0.2 UG/DAY FLUOCINOLONE ACETONIDE INTRAVITREAL INSERTS TO SHAM INJECTION IN SUBJECTS WITH DIABETIC OSTEOCYTE SCLEROSTIN RESPONSE TO MECHANICAL FOR ENHANCING THE DELIVERY OF RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2 IN A NON HUMAN REMODELING SIMULATION TO STUDY THE MECHANICAL ADAPTABILITY AND FATIGUE RESISTANCE OF BONE INTRAOSSEOUS VASCULAR ANATOMY OF THE HUMAN ROLE OF TENSIN GENES IN TISSUE REGENERATION AND LONG TERM EFFECTS OF BISPHOSPHONATE THERAPY ON BONE EFFECTS OF JOINT REPLACEMENT ON CARDIOVASCULAR FITNESS, LIKE MOLECULE (IL-17RL) IN PROSTATE CANCER AND ARTICULAR CARTILAGE SURFACE REGENERATION A BIOMECHANICAL STUDY OF REPAIR TECHNIQUES FOR SPONDYLOLYTIC PATHOLOGY & LABORATORY MEDICINE ELLIS, VASCULATURE, ISCHEMA AND BEHAVIOR - CORE C PATHOLOGY & LABORATORY MEDICINE GREGG, CHEMOPREVENTION IN A MOUSE MODEL FOR DCIS DEATH REGISTRY SYSTEM - TRAINING, MAINTENANCE AND OPERATIONS (CA- clinical studies in nutrition and metabolism the use of novel amyloid binding ligands for anti- PRECISION, ACCURACY AND CLINICAL EFFECTIVENESS performance evaluation of hemocue glucose rt system CLINICAL EVAL OF GOLD (ACCU-CHEK PERFORMA) GLUCOSE MONITORING FUNGINEMIA WITH RAPID NUCLEIC ACID TESTING: mecp2, methyl deficiency and hepatic tumorigenesis ASSESSMENT OF VITAMIN B12 BIOAVAILABILITY FROM BEEF GENE THERAPY TO LOWER SERUM HOMOCYSTEINE IN A MOUSE MODEL FUNCTIONAL CHARACTERIZATION OF THE AMINOTERMINUS OF SIV A PHASE III RANDOMIZED, MULTINATIONAL STUDY, DOUBLE BLINDED FOR THE IMMUNOGENICITY AND CONSISTENCY EVALUATION OF 3 HIB-MEDCYTT VACCINE LOTS AND SINGLE BLINDED AND CONTROLLED FOR THE EVALUATION OF SAFETY AND IMMUNOGENICITY OF GSK BIOLOGICALS HAEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA GAIN INSIGHT INTO HIV AND AIDS IN CHILDREN NUTROPIN AQ, NUTROPIN AND NUTROPIN DEPOT IN CHILDREN WITH GROWTH FAILURE DUE TO CHRONIC RENAL INSUFFICIENCY OR BIOACTIVITY AND VITAMINS IN FLASH HEATED BREASTMILK cases for molecular epidemiology of childhood leukemia HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 CEREBRAL EDEMA IN PEDIATRIC KETOACIDOSIS EMPHASIS ON NEURODEVELOPMENTAL DISORDERS UNIVERSITY CTR FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES, EDUCATION, RES AND SERVICE IMPROVING THE CARE OF ACUTELY ILL AND INJURED CHILDREN IN RURAL EMERGENCY DEPARTMENTS WITH TELEMEDICINE 2006-07 CYSTIC FIBROSIS FOUND ACCREDITATION AND FUNDING AN ETHNOGRAPHIC STUDY OF ADOLESCENT DATING VIOLENCE: COMMUNITY PARTNERSHIPS WITH PEDIATRICIANS FOR PROJ TO RURAL FIRST AMERICANS VIA TELEHEALTH ANNUAL GENE THERAPY SYMPOSIUM FOR LUNG AND BLOOD DISEASES MESENCHYMAL STEM CELLS FOR FETAL GENE DELIVERY CHARACTERIZATION USING LASER TWEEZERS RAMAN IMMUNOTHERAPY FOR DIABETIC COMPLICATIONS POSITIONAL CLONING OF OBESITY GENES FROM RAPID ISOLATION OF DIET-RESPONSIVE OBESITY CHILDREN’S ONCOLOGY GROUP (COG) RES PROG CNMC0601 RANDOMIZED STUDY OF DAILY VS. HIGH DOSE WEEKLY PREDNISONE THERAPY IN DUCHENNE rehabilitation res & training ctr in neuromuscular disease: enhancing health, function, and quality of life regulation of the synaptic localization of the nachr MECHANISMS OF RELEASE AND ROLE OF T CELL EXOSOMES IN BLOOD-BRAIN BARRIER IN CEREBRAL ISCHEMIA K-C1 COTRANSPORTERS IN RAT NERVOUS SYSTEM CFTR VS. CA-ACTIVATED CHLORIDE CHANNELS IN evaluation of face processing with psychophysiological and eeg indices of negative affect in children with autism or HEALTH DISPARITIES IN PATIENTS WITH CHRONIC PSYCHOTIC DISORDERS VERSUS NON-PSYCHOTIC TRACKING THE COURSE OF MATHEMATICAL LEARNING brain based measures for treatment development of CHILD AND ADOLESCENT PSYCHIATRY AT UC DAVIS BLIND, PARALLEL GROUP, PLACEBO CONTROLLED PHASE IIIB STUDY OF THE EFFICACY AND SAFETY OF QUETIAPINE FUMARATE (SEROQUEL) IMMEDIATE RELEASE TABLETS IN DAILY DOSES OF 400 MG AND 800 MG COMPARED WITH MULTICENTER, OPEN LABEL PHASE IIIB STUDY OF THE SAFETY AND TOLERABILITY OF QUETIAPINE FUMARATE (SEROQUEL) IMMEDIATE RELEASE TABLETS IN DAILY DOSES OF 400 MG AND 800 MG IN CHILDREN WITH BIPOLAR I DISORDER AND BLIND, CONTROLLED STUDY OF TWO FIXED ORAL DOSES OF ARIPIPRAZOLE IN THE TOLERABILITY STUDY OF FLEXIBLE DOSE ORAL ADOLESCENT PATIENTS WITH SCHIZOPHRENIA AND CHILD AND ADOLESCENT PATIENTS WITH BIPOLAR I DISORDER, MANIC OR STUDY OF ESCITALOPRAM IN PEDIATRIC PATIENTS BLIND, PLACEBO CONTROLLED STUDY OF TWO FIXED ORAL DOSES OF ARIPIPRAZOLE (10MG AND 30MG) IN THE TREATMENT OF CHILD AND ADOLESCENT PATIENTS, AGES 10-17, WITH BIPOLAR 1 DISORDER, MANIC OR MIXED EPISODE AGGRESSIVE BEHAVIOR IN FRAGILE X SYNDROME GAZE PATTERNS IN AUTISM ACROSS THE FIRST TWO INTERDISCIPLINARY TRAINING FOR AUTISM RESEARCHERS DEFINITION AND DEVELOPMENT OF THE PHENOTYPE OF AUTISM COGNITIVE SEQUELAE OF METHAMPHETAMINE ABUSE NUMERICAL DEFICITS ACROSS MULTIPLE GENETIC STAR): PILIPINA BREAST CANCER SUPPORT GROUP OUTREACH (AANCART) IMPACT OF INTERPRETERS ON CANCER CARE ACCESS AND DELIVERY FOR THAI SWAN SLEEP STUDY II-UC DAVIS/ KAISER SITE STUDY OF WOMEN’S HEALTH ACROSS THE NATION III METHODS DEVELOPMENT FOR EXPOSURE RELATED BEHAVIORS EARLY CHILDHOOD DEVELOPMENT AND PCB EXPOSURES IN SLOVAKIA POLYBROMINATED DIPHENYL ETHERS AS A POTENTIAL costs of occupational injury and illness NEEDS ASSESSMENT FOR THE UC DAVIS SCHOOL OF PATIENTS RECEIVING THERAPEUTIC RADIATION HYBRID NUCLEAR X-RAY PROJECTION SYSTEM FOR INTRAVENOUSLY ADMINISTERED NONIONIC CONTRAST MEDIA technique and patient outcomes in laparoscopic A NOVEL THERAPY FOR PANCREAS AND PROSTATE DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER, DOSE SELECTION STUDY OF AD2/HYPOXIA INDUCIBLE USING A SPRAY APPLICATOR IN SUBJECTS UNDERGOING AUTOLOGOUS SKIN GRAFTING FOLLOWING BURN OR TRAUMATIC skin EFFICACY OF NEOADJUVANT XELOX THERAPY FOR GALECTIN LEVELS AND APOPTOSIS IN KELOID AND NORMAL FIBROBLASTS SACRAMENTO TRAUMA CTR ALCOHOL INTERVENTION PKC ISOENZYMES AND DIABETIC MICROVASCULAR MICROVASCULAR BARIER DYSFUNCTION IN THERMAL NEUTROPHIL DEPENDENT REGULATION OF VENULAR CANCER CTR SUPPORT GRANT- CURE SUPPLEMENT OF H2 RELAXIN AS A FACILITATOR OF ANDROGEN har alterations and androgen-independant

Source: http://mdscholars.ucdavis.edu/funding%20sources/SOMGrantsDec2006.pdf

Layout

PACKER severe allergy treatment Plan nursing Office: tel. 718 250-0259 Fax: 718 250-0292 [email protected] _______________________________________________________________________________student’s last name, First name, middle name ________________________________________________________________________________________ complete Physician’s instructions. sign and date all areas.

3.2_v2.qxd

Using Business Intelligence to Discover New Market OpportunitiesUsing Business Intelligenceto Discover New MarketOpportunitiesJanice FratesCalifornia State University Long BeachMany companies have customers of which theyBusiness Intelligence, Marketing, Competition,are only minimally aware, people who started using agiven product while seeking a solution for an appar-ently unrelated need. Th

© 2008-2018 Medical News